Comparative Pharmacology
Head-to-head clinical analysis: DEXILANT versus PREVACID NAPRAPAC 250 COPACKAGED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXILANT versus PREVACID NAPRAPAC 250 COPACKAGED.
DEXILANT vs PREVACID NAPRAPAC 250 (COPACKAGED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexlansoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
Lansoprazole: Proton pump inhibitor that irreversibly inhibits H+/K+ ATPase in gastric parietal cells, reducing gastric acid secretion. Naproxen: Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
30 mg orally once daily for up to 8 weeks; for healing esophagitis, 60 mg orally once daily for up to 8 weeks; maintenance 30 mg orally once daily.
Lansoprazole 15 mg plus naproxen 250 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is 1–2 hours in healthy subjects, but due to prolonged gastric acid suppression via irreversible binding to proton pumps, duration of action exceeds 24 hours. Half-life is not directly correlated with pharmacodynamic effect.
Naproxen: 12-17 hours (terminal), allows twice-daily dosing. Lansoprazole: 1-2 hours (terminal), but acid suppression persists due to accumulation in parietal cells.
Renal (approximately 50% as inactive metabolites) and fecal (approximately 50% as inactive metabolites).
Naproxen: Renal (95% as unchanged drug and metabolites, primarily 6-O-desmethyl naproxen), fecal (<5%). Lansoprazole: Renal (20% as metabolites), fecal (80% as metabolites).
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor/NSAID Combination